https://www.cypralis.com/ 1.0 monthly 2022-06-08 https://www.cypralis.com/about-us/company-overview 1.0 monthly 2022-06-08 https://www.cypralis.com/about-us/board-and-management 1.0 monthly 2022-06-08 https://www.cypralis.com/about-us/scientific-advisors 1.0 monthly 2023-05-26 https://www.cypralis.com/technology/about-cyclophilins 1.0 monthly 2022-06-08 https://www.cypralis.com/technology/therapeutic-potential-inhibitors 1.0 monthly 2022-06-08 https://www.cypralis.com/technology/cypralis-assets 1.0 monthly 2022-06-08 https://www.cypralis.com/pipeline 1.0 monthly 2022-06-08 https://www.cypralis.com/pipeline/cc-4066-delayed-graft-function 1.0 monthly 2022-06-08 https://www.cypralis.com/pipeline/cc-4066-organ-preservation 1.0 monthly 2022-06-08 https://www.cypralis.com/pipeline/cc-4066-in-acute-pancreatitis 1.0 monthly 2022-06-08 https://www.cypralis.com/partnerships 1.0 monthly 2022-06-08 https://www.cypralis.com/news 1.0 monthly 2022-06-08 https://www.cypralis.com/contact 1.0 monthly 2022-06-08 https://www.cypralis.com/terms-and-conditions 1.0 monthly 2022-06-08 https://www.cypralis.com/privacy-policy 1.0 monthly 2022-06-08 https://www.cypralis.com/cypralis-has-launched-to-focus-on-developing-novel-medicines-for-degenerative-diseases 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-announces-innovate-uk-award-to-generate-selective-cyclophilin-d-inhibitors-targeting 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-limited-announces-collaboration-with-johnson-johnson-innovation-in-the-field-of-neurodegenerative 0.8 monthly 2022-04-08 https://www.cypralis.com/neurodegenerative-diseases-the-potential-of-cyclophilin-inhibition 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-limited-announces-appointment-of-dr-michael-peel-as-chief-scientific-officer 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-limited-announces-agreement-with-scynexis-inc-to-acquire-a-large-portfolio-of-cyclophilin-inhibitor 0.8 monthly 2022-04-08 https://www.cypralis.com/changing-shapes-from-proteins-to-business-models 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-granted-new-innovate-uk-early-stage-award-to-develop-cyclophilin-d-inhibitors-targeting 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-selcia-and-gilead-publish-synthetic-macrocyclic-cyclophilin-inhibitors-inspired 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-limited-announces-grant-award-from-alzheimers-drug-discovery-foundation 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-granted-new-innovate-uk-feasibility-stage-award-to-develop-cyclophilin-inhibitors 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-to-present-pre-clinical-data-on-novel-cyclophilin-d-inhibitor-cc-1233-for-acute-pancreatitis 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-and-gilead-sciences-inc-agree-on-license-terms-under-which-cypralis-will-hold-exclusive 0.8 monthly 2022-04-08 https://www.cypralis.com/cypralis-ceo-presents-to-prospective-investors-at-this-year-s-biotech-and-money-world-congress 0.8 monthly 2022-04-08 https://www.cypralis.com/identification-of-synthetic-macrocyclic-orally-bioavailable-cyclophilin-inhibitors-with-potent-hcv 0.8 monthly 2022-04-08